For the quarter ended June 2025, Insmed (INSM Quick QuoteINSM - Free Report) reported revenue of $107.42 million, up 18.9% over the same period last year. EPS came in at -$1.70, compared to -$1.94 in the year-ago quarter.

The reported revenue represents a surprise of +3.87% over the Zacks Consensus Estimate of $103.42 million. With the consensus EPS estimate being -$1.30, the EPS surprise was -30.77%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Insmed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- U.S.: $68.68 million compared to the $71.75 million average estimate based on four analysts. The reported number represents a change of +7.7% year over year.
• Revenue- Europe and rest of world: $8.06 million compared to the $6.57 million average estimate based on three analysts. The reported number represents a change of +48.3% year over year.
• Revenue- Japan: $30.67 million compared to the $26 million average estimate based on three analysts. The reported number represents a change of +45.3% year over year.

View all Key Company Metrics for Insmed here>>>

Shares of Insmed have returned +15.3% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.